These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 17083769)

  • 21. Responsiveness and discriminative capacity of the assessments in ankylosing spondylitis disease-controlling antirheumatic therapy core set and other outcome measures in a trial of etanercept in ankylosing spondylitis.
    Wanders AJ; Gorman JD; Davis JC; Landewe RB; van der Heijde DM
    Arthritis Rheum; 2004 Feb; 51(1):1-8. PubMed ID: 14872448
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Treatment of ankylosing spondylitis and undifferentiated spondyloarthritis with TNF alpha-antagonists].
    Brandt J; Sieper J; Braun J
    Z Rheumatol; 2003 Jun; 62(3):218-27. PubMed ID: 12827397
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness, safety, and predictors of good clinical response in 1250 patients treated with adalimumab for active ankylosing spondylitis.
    Rudwaleit M; Claudepierre P; Wordsworth P; Cortina EL; Sieper J; Kron M; Carcereri-De-Prati R; Kupper H; Kary S
    J Rheumatol; 2009 Apr; 36(4):801-8. PubMed ID: 19273449
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Interferon regulatory factor (IRF)-5: a potential therapeutic target for ankylosing spondylitis.
    Xu WD; Ye DQ
    Rheumatol Int; 2012 Dec; 32(12):4065-7. PubMed ID: 21928121
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of infliximab in patients with ankylosing spondylitis: results of a randomized, placebo-controlled trial (ASSERT).
    van der Heijde D; Dijkmans B; Geusens P; Sieper J; DeWoody K; Williamson P; Braun J;
    Arthritis Rheum; 2005 Feb; 52(2):582-91. PubMed ID: 15692973
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of the Bath Ankylosing Spondylitis Disease Activity Index and a modified version of the index in assessing disease activity in patients with ankylosing spondylitis without peripheral manifestations.
    Song IH; Rudwaleit M; Listing J; Sieper J
    Ann Rheum Dis; 2009 Nov; 68(11):1701-7. PubMed ID: 19029168
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Anti-TNF alfa therapy in ankylosing spondylitis].
    Cravo AR; Tavares V; Da Silva JC
    Acta Med Port; 2006; 19(2):141-50. PubMed ID: 17187716
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [The role of biologic agents in the therapy of ankylosing spondylitis].
    Géher P; Nagy MB; Péntek M; Tóth E; Brodszky V; Gulácsi L
    Orv Hetil; 2006 Jul; 147(26):1203-13. PubMed ID: 16898082
    [TBL] [Abstract][Full Text] [Related]  

  • 29. How early should ankylosing spondylitis be treated with tumour necrosis factor blockers?
    Sieper J; Rudwaleit M
    Ann Rheum Dis; 2005 Nov; 64 Suppl 4(Suppl 4):iv61-4. PubMed ID: 16239391
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Anti-TNFα therapy in ankylosing spondylitis: symptom control and structural damage modification].
    Andreu JL; Otón T; Sanz J
    Reumatol Clin; 2011; 7(1):51-5. PubMed ID: 21794779
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of refractory inflammatory monoarthritis in ankylosing spondylitis by intraarticular injection of infliximab.
    Schatteman L; Gyselbrecht L; De Clercq L; Mielants H
    J Rheumatol; 2006 Jan; 33(1):82-5. PubMed ID: 16292792
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Treatment of ankylosing spondylitis.
    Clegg DO
    J Rheumatol Suppl; 2006 Sep; 78():24-31. PubMed ID: 17042057
    [TBL] [Abstract][Full Text] [Related]  

  • 33. 2010 Update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis.
    van der Heijde D; Sieper J; Maksymowych WP; Dougados M; Burgos-Vargas R; Landewé R; Rudwaleit M; Braun J;
    Ann Rheum Dis; 2011 Jun; 70(6):905-8. PubMed ID: 21540200
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Ankylosing spondylitis and symptom-modifying vs disease-modifying therapy.
    Akkoc N; van der Linden S; Khan MA
    Best Pract Res Clin Rheumatol; 2006 Jun; 20(3):539-57. PubMed ID: 16777581
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Withdrawal of biologic therapy in axial spondyloarthritis: the experience in early disease.
    Song IH; Haibel H; Poddubnyy D; Braun J; Sieper J
    Clin Exp Rheumatol; 2013; 31(4 Suppl 78):S37-42. PubMed ID: 24129135
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Current therapy with TNFalpha blocking agents for ankylosing spondylitis and undifferentiated spondyloarthritis].
    Brandt J; Sieper J; Braun J
    Z Rheumatol; 2004 Jun; 63(3):203-10. PubMed ID: 15224223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. New treatment targets in ankylosing spondylitis and other spondyloarthritides.
    Song IH; Poddubnyy D
    Curr Opin Rheumatol; 2011 Jul; 23(4):346-51. PubMed ID: 21508843
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The epidemiology of ankylosing spondylitis and the commencement of anti-TNF therapy in daily rheumatology practice.
    Vander Cruyssen B; Ribbens C; Boonen A; Mielants H; de Vlam K; Lenaerts J; Steinfeld S; Van den Bosch F; Dewulf L; Vastesaeger N
    Ann Rheum Dis; 2007 Aug; 66(8):1072-7. PubMed ID: 17261531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A tailored approach to reduce dose of anti-TNF drugs may be equally effective, but substantially less costly than standard dosing in patients with ankylosing spondylitis over 1 year: a propensity score-matched cohort study.
    Závada J; Uher M; Sisol K; Forejtová Š; Jarošová K; Mann H; Vencovský J; Pavelka K
    Ann Rheum Dis; 2016 Jan; 75(1):96-102. PubMed ID: 25165033
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Evaluation of the nonsteroidal anti-inflammatory drug-sparing effect of etanercept in axial spondyloarthritis: results of the multicenter, randomized, double-blind, placebo-controlled SPARSE study.
    Dougados M; Wood E; Combe B; Schaeverbeke T; Miceli-Richard C; Berenbaum F; Koppiker N; Dubanchet A; Logeart I
    Arthritis Res Ther; 2014 Nov; 16(6):481. PubMed ID: 25428762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.